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some normal-looking, glomeruli as well as diffuse interstitial
scarring with a few inflammatory cells and foci of foam cells.
Immunofluorescence studies disclosed only faint, focal staining
for IgM, fibrinogen, and C3 along some vessel walls. No specific
diagnosis was made.
Twenty months after transplantation, a hearing defect was
detected at school. An audiogram revealed a symmetric loss of
about 50 dB in the 1000 to 8000 Hz range, a loss typical of
sensorineural deafness (Fig. 1). A diagnosis of Alport’s syndrome
(AS) was suspected. Ophthalmologic evaluation failed to show
lenticonus and macular flecks. Electron microscopic examina-
tion of the nephrectomy specimen revealed a grossly abnormal
appearance of the glomerular basement membrane (GBM)
typical of Alport’s syndrome, including irregular contours, ar-
eas of thinning, and marked thickening and splitting with inclu-
sion of electron-dense granules in electron-lucent areas (Fig. 2).CASE PRESENTATION
Despite the absence of renal disease in this family, a clinicalAn 11-year-old girl was referred 10 years ago to the Cliniques
and genetic screening of the first relatives was proposed. TheUniversitaires St. Luc for renal transplantation. At age 7, dip-
parents told us for the first time that they were first cousins;stick proteinuria and microscopic hematuria had been discov-
this information raised the suspicion of a recessive form ofered at a school examination. Workup performed at that time
Alport’s syndrome. Both parents and the patient’s three sib-at another hospital revealed a serum creatinine of 0.5 mg/dl,
lings had normal urinalyses and normal serum creatinine levels.marked proteinuria (3.3 g/liter), and 100 red blood cells/high-
The father was mildly hypertensive and had a bilateral, sym-power field on microscopy of the urine sediment; intravenous
metric hearing loss in the 3000 to 6000 Hz range, attributedpyelography was normal. The patient’s parents declined a renal
to his work in a noisy environment. The mother and the threebiopsy. The patient was lost to follow-up for four years. She
siblings had normal blood pressure and normal audiograms,then presented at age 11 with end-stage renal failure (creatinine
except for a slight unilateral hearing loss in one sister.clearance, 2.6 ml/min/1.73 m2). Ultrasonographic examination
Linkage analysis using six genetic markers near and withindisclosed symmetrically reduced kidneys. Proteinuria and mi-
the COL4A5 gene, the gene responsible for the X-linked formcroscopic hematuria were again detected. Serologic tests, in-
of Alport’s syndrome, showed that one unaffected brother hadcluding complement studies, were unremarkable. There was no
received from his mother a copy of the same haplotype as thefamily history of renal disease. The patient’s mother proposed
proband. Thus the COL4A5 gene was not responsible fordonating a kidney to her daughter. The mother’s assessment did
the disease in this family. In fact, both the consanguinity andnot reveal any abnormality, and transplantation was performed
the development of renal failure in a very young female stronglytwo months after initiation of hemodialysis.
suggested a recessive form of Alport’s syndrome involving thePost-transplantation immunosuppression included antilym-
COL4A3 or COL4A4 gene. Direct sequencing of PCR prod-phocyte globulin, cyclosporine, azathioprine, and prednisolone.
ucts from the first five exons of COL4A3 (counted from theThe patient was discharged 13 days after surgery with a serum
39 end of the gene) disclosed a homozygous single-base substi-creatinine of 0.6 mg/dl. No rejection episode occurred. Histo-
tution of T to C in exon 5 of COL4A3; this mutation replaceslogic examination of the kidney removed at the time of trans-
an arginine codon with a stop codon, shortening the a3(IV)plantation showed on light microscopy mostly sclerotic, but also
chain by 190 amino acids [1]. Further immunohistochemical
study of the preserved glomeruli and tubules from the nephrec-
tomy specimen revealed no fixation of anti-a3, -a4, and -a5(IV)Presentation of this Forum is made possible by grants from Merck &
antibodies in the GBM, whereas isolated staining of anti-Company, Incorporated; Astra Pharmaceuticals; Hoechst Marion
a5(IV) was observed in the basement membranes of Bowman’sRoussel, Incorporated; Dialysis Clinic, Incorporated; Amgen, Incorpo-
capsules and collecting ducts (Fig. 3), a pattern consistent withrated; and R & D Laboratories, Incorporated.
the autosomal-recessive form of Alport’s syndrome [2].
Key words: COL4A5 gene, hereditary nephritis, type-IV collagen, The patient was given information on the recessive nature of
hematuria, proteinuria, end-stage renal failure, glomerular basement her disease. She subsequently became pregnant and gave birth
membrane, lenticonus. one year ago to a normal girl. She is currently doing well 10
years after transplantation and has normal graft function. Her 1999 by the International Society of Nephrology
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Fig. 1. Tonal audiometry showing a bilateral, symmetric loss (in decibels or dB) most marked in high tones (1000–8000 Hertz). Hatched rectangle
is the area of conversational speech.
Fig. 2. Electron photomicrograph of glomerular basement membrane, showing segments of thickening and thinning with irregular contours (left
panel). Magnification of a thickened segment showing lamellation, electron-lucent areas and electron-dense granules (right panel). Courtesy of
Dr. J.P. Cosyns.
maintenance daily immunosuppressive regimen includes cyclo- the case presentation illustrates, the diagnosis of Alport’s
sporine, 2 mg/kg; azathioprine, 1 mg/kg; and prednisolone, 0.1 syndrome can escape a physician’s attention in the ab-
mg/kg.
sence of a family history of the disease. Furthermore,
even after the recognition of both sensorineural deafness
DISCUSSION and GBM abnormalities, this case would not have met
the strict diagnostic criteria proposed 10 years ago forDr. Yves Pirson (Clinical Professor, Service de
“classic” AS [3], because both a family history and oph-Ne´phrologie, Universite´ Catholique de Louvain, Clin-
iques Universitaires Saint-Luc, Brussels, Belgium): As thalmic signs were absent. Since identification of the
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Fig. 3. Immunostaining of the nephrectomy spectrum with antia5 (IV) antibodies, showing expression in basement membranes of collecting ducts.
Courtesy of Dr. M.C. Gubler.
genes responsible for AS, first the “classic” X-linked in [6, 7]. Estimated gene frequency is 1:5000 to 1:10000; AS
accounts for 1% to 2% of cases of end-stage renal failure1990 [4] and in 1994 the autosomal-recessive forms [1],
genetic mutation detection has become the ultimate and (ESRF) in Western countries [8]. Alport’s syndrome is
caused by defects in type-IV collagen, a major compo-sufficient diagnostic criterion. However, mutation analy-
sis of the AS genes remains a tedious and sometimes nent of basement membranes. Type-IV collagen is com-
posed of three a-chains that form a triple helical mole-unsuccessful task because the incriminated genes contain
more than 50 exons and there is no “hot spot.” The cule. Each a-chain consists of a central domain (the
collagenous domain), an amino terminal end (the 7Sdevelopment of new DNA analyses such as the chip
technology could improve the yield of mutation screen- domain), and a globular carboxy terminal end (the non-
collagenous domain or NC1 domain) [9]. Six geneticallying in the near future [5]. In the meantime, the diagnosis
of AS rests in the majority of cases on a careful stepwise distinct type-IV collagen a-chains, a1(IV) through
a6(IV), have been identified. They are encoded by genesapproach exemplified by the case presentation: careful
collection and analysis of family history and clinical fea- (called COL4A1 to A6) arranged pairwise on three dif-
ferent chromosomes: COL4A1 and COL4A2 on chro-tures, electron microscopic and immunohistologic exam-
ination of basement membranes, and genetic linkage mosome 13, COL4A3 and COL4A4 on chromosome 2,
and COL4A5 and COL4A6 on chromosome X [10]. Theanalysis. After a brief review of the pathogenesis of the
disease, I will critically review the diagnostic value of a1(IV) and a2(IV) chains are present in all basement
membranes; mutations in their genes are likely to beeach clinical and pathologic feature and propose a diag-
nostic strategy. lethal in the embryo [10]. By contrast, the a3, a4, a5, and
a6(IV) chains are expressed selectively in the basementAlport’s syndrome is characterized by a progressive
glomerulonephritis erratically associated with various membranes of some tissues, including those potentially
involved in AS, that is, kidney, cochlea, and eye [11].extrarenal features, mainly auditory and ocular defects
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In approximately 85% of AS pedigrees, the disease gross hematuria; interestingly, microscopic hematuria is
found in about one-half of AR heterozygotes [1, 12].is X-linked and mutations identified so far are in the
COL4A5 gene. Of 176 mutations in the COL4A5 gene Proteinuria, usually absent in the first years of life,
eventually appears in all hemizygotes and AR homozy-recorded by Lemmink and coworkers, 38 are large- and
medium-sized deletions (ranging from a single exon to gotes and can lead to the nephrotic syndrome in as many
as 30% of patients [6–8]. Proteinuria is recorded in two-the complete gene) and 138 are small mutations of all
types (mis-sense: 62; frameshift group including small thirds of XL heterozygotes [8].
Not unexpectedly, the risk of progression to end-stagedeletion, insertion, splice site and non-sense: 69; inframe
group including deletion and duplication: 7) [12]. The renal failure is the highest among hemizygotes and AR
homozygotes. In hemizygotes, the probability of devel-mutations are interspersed along the gene. New muta-
tions comprise 10% to 15%, a proportion comparable oping ESRF is 90% by the age of 40 (abstract, Gubler
et al, J Am Soc Nephrol 9:388A, 1998). According to thewith that found in other X-linked disorders [12]. In the
few X-linked families with associated leiomyomatosis, age at ESRF in hemizygotes, X-linked AS is said to be
of either the juvenile or the adult type, the arbitrary cut-Antignac and Heidet have identified contiguous dele-
tions involving both the COL4A5 and the COL4A6 off being 31 years [18]. The juvenile type is encountered
in three-quarters of kindreds. In XL heterozygotes, thegenes [13]. So far, no mutation solely within the COL4A6
gene has been reported in patients with AS. probability of developing ESRF is 12% by the age of 40
and 30% by the age of 60 (abstract; Gubler et al, ibid);In the majority of the non-X-linked families, the trans-
mission appears to be autosomal recessive, with muta- risk factors for progression are a history of gross hematu-
ria in childhood, nephrotic syndrome, and diffuse GBMtions detected in either the COL4A3 or the COL4A4
gene; Lemmink et al have recorded nine different muta- thickening [19].
Renal prognosis also depends on the kind of mutation.tions (six in COL4A3, three in COL4A4) [12]. Of inter-
est, mutations in the COL4A3/A4 genes appear to be Among hemizygotes the probability of ESRF before the
age of 30 is significantly higher (90%) in individuals withinvolved in a subset of patients with so-called benign
familial hematuria [14] and perhaps also in a rare, autoso- a large rearrangement of COL4A5 or a small mutation
leading to a stop codon than in those with a splice-sitemal-dominant, form of AS [15]. I will discuss these pre-
liminary data briefly in a moment. (70%) or mis-sense (50%) mutation (abstract; Gubler
et al, ibid). As a result, a good concordance usually exists
Clinical features for the age of onset of ESRF among affected relatives [8],
especially in the juvenile type. Still, a large intrafamilialIn the X-linked form of AS, the disease is consistently
severe in affected males (hemizygotes) and usually much variability—as indicated by a more than 20-year differ-
ence in the age at ESRF in related hemizygotes—hasless symptomatic in affected females (referred to as XL
heterozygotes); the wide range of severity observed in been reported in the adult type [20–22]. A more than
10-year difference in the age at ESRF also has beenfemales is ascribed to the well-known random inactiva-
tion of one of the X chromosomes [16]. In the autosomal- observed among related AR homozygotes [1, 23].
Hearing defect. Sensorineural deafness used to be arecessive form, the disease is, as expected, as severe in
male as in female homozygotes or in the rare compound prerequisite for the diagnosis of AS [3]. It is now clear
that hearing is not impaired in some families with X-heterozygotes, referred to collectively as AR homozy-
gotes for the sake of simplicity; mild clinical manifesta- linked as well as with autosomal-recessive AS [1, 7, 12].
Hearing loss is never present at birth. Generally (buttions are occasionally observed in carriers of the autoso-
mal recessive form (referred to as AR heterozygotes). not always, as exemplified in the case presentation),
hearing loss becomes symptomatic before the onset ofRenal disease. Hematuria is the key clinical feature in
AS. Just as in other glomerular diseases, examination of renal failure. In the early stage, it is detectable only by
audiometry, revealing a bilateral high tone loss (definedthe urine frequently reveals red blood cell casts and, in
phase-contrast microscopy, acanthocyturia [6]. In the X- as 230 dB) most marked in the 2000 to 8000 Hz fre-
quency range [7, 24]. Serial studies demonstrate a pro-linked form, microscopic hematuria is observed in all
males and in 95% of females [17]. In hemizygotes, micro- gressive loss of as much as 50 to 70 dB, as well as loss
at lower frequencies [7, 24]. Hearing loss can affect con-scopic hematuria is constant from infancy, whereas it
can be intermittent in XL heterozygotes. Episodes of versational speech to the extent that patients require a
hearing aid.gross hematuria occur in 60% to 70% of hemizygotes
(sometimes after an upper respiratory tract infection, The risk of developing hearing loss by the age of 40
is about 90% for hemizygotes and 10% for XL heterozy-just as in IgA nephropathy), most often before the age
of 15 [8], and in one-third of XL heterozygotes [8, 17]. gotes (abstract; Gubler et al, ibid). Hearing loss is present
in about two-thirds of AR homozygotes, usually beforeIn the autosomal-recessive form, all AR homozygotes
have microscopic hematuria and many have episodes of the age of 20 [12].
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Table 1. Non-Alport hereditary disorders that may include renal involvement and hearing loss
Disease Ref. Renal involvement Hearing deficit Main other abnormalities Genetics
Mitochondrial 26, 27 Nonspecific tubular Sensorineural Diabetes, short stature, A3243G
cytopathy and glomerular lesions cardiomyopathy mutation
in mtDNAa
Muckle-Wells 28 AA amyloidosis Sensorineural Bouts of fever and Unclear
syndrome angioedema-like symptoms
Refsum’s disease 8 Storage nephropathy Sensorineural Retinitis pigmentosa, AD, gene
peripheral neuropathy, unknown
cerebellar ataxia
Cockayne’s 29 Nonspecific Sensorineural Photosensitivity, AR, gene
syndrome glomerulosclerosis retinitis pigmentosa, unknown
poor growth
Branchio-oto- 29 Agenesis and/or Sensorineural, Preauricular pits, AD, EYA1
renal syndrome hypo/dysplasia 6 conductive branchial fistulae, gene
cysts or mixed facial dysmorphy (chrom 8)
Bardet-Biedl 29 Dysplasia Sensorineural Retinitis pigmentosa, AR, loci at
syndrome obesity, polydactyly chrom 3, 11
hypogenitalism in males 15, 16
Alstro¨m’s 29 Dysplasia Sensorineural Retinitis pigmentosa, AR, locus
syndrome obesity, polydactyly at chrom 2
Charcot-Marie- 30 Nonspecific Sensorineural Slowly progressive AD, gene
Tooth syndrome glomerulosclerosis neuromuscular atrophy unknown
Distal tubular 31 Metabolic acidosis 6 Sensorineural — AR, gene
acidosis nephrocalcinosis unknown
a mtDNA: mitochondrial DNA; AD: autosomal dominant; AR: autosomal recessive
Just as for renal prognosis, hearing loss is determined pain complicated by AA amyloidosis and the eventual
development of the nephrotic syndrome [28]. Cockayneby the kind of mutation: among hemizygotes the proba-
bility of developing hearing loss before the age of 30 is syndrome is characterized by a variety of clinical features
including glomerulonephritis, photosensitivity, preco-significantly lower in those with a mis-sense mutation
than in those with other types of mutation (abstract; cious senile appearance, neurologic abnormalities, and
retinitis pigmentosa [29]. Various associations betweenGubler et al, ibid). Of note, a specific COL4A5 mis-
sense mutation, found in 87 males from nine US families malformed ears, hearing loss, and renal abnormalities
have been described; the most common is the branchio-sharing a common ancestry, is associated with a remark-
able late-onset hearing loss, reported in only 60% of oto-renal syndrome [29]. Bardet-Biedl syndrome, as well
as its variant, Alstro¨m’s syndrome (in which hypogeni-patients by age 60, 10 years on average after ESRF [22];
interestingly, the age at which hearing loss becomes ap- talism is absent), can include both renal cystic dysplasia
and deafness [29]. A few patients with the Charcot-Marie-parent is highly variable in this family (with an interval
of as long as 30 years) [22]. Tooth syndrome have focal segmental glomerulosclerosis
associated with hearing loss [30]. Sensorineural deafnessLimited information is available on the histology of
the inner ear in patients with AS. Data point to the stria also has been reported in patients with the autosomal-
recessive, but not the autosomal-dominant, form of distalvascularis of the cochlea as the site of the most striking
alterations [7]. In a mouse model of AS, a marked thick- tubular acidosis [31]. One family with autosomal-domi-
nant hypoparathyroidism, sensorineural deafness, andening of the basement membranes of the strial vessels
has been observed [25]. renal dysplasia has been reported [32].
Ocular abnormalities. Ophthalmic abnormalities oc-Sensorineural deafness developing in the presence of
nephropathy should suggest several other hereditary dis- cur in about one-half of AS patients (Table 2). Reported
ocular changes include anterior lenticonus and retinalorders (Table 1) [9], which are rarer, and therefore less
well known, than AS. A specific mitochondrial DNA flecks. In addition, we have described recurrent, non-
traumatic corneal erosions [33]. Lenticonus is a localized(mtDNA) mutation (a guanine for adenine substitution
at position 3243) is responsible for a syndrome combin- conical (hence its name) protrusion of the central portion
of the lens, most often into the anterior chamber of theing diabetes mellitus, sensorineural deafness, and pro-
gressive renal failure [26, 27]; remarkably, several re- eye. Anterior lenticonus was recorded in 22% of 94 AS
patients younger than 25 years (Table 2). Anterior lenti-ported patients had been misdiagnosed as having AS [27].
The manifestations of the other listed diseases are clearly conus, the most specific extrarenal manifestation of AS,
is pathognomonic of AS [34]. It also is a valuable markerdifferent from AS. Muckle-Wells syndrome is character-
ized by recurrent bouts of fever with urticaria and limb of the severity of AS, being consistently associated with
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Table 2. Prevalence of main ocular abnormalities in 94 AS patients younger than 25 years old
Number of patients with
Posterior
Number of Any ocular Anterior Retinal polymorphous
Ref. patients/males abnormality lenticonus flecks dystrophy
24 51/43 23 10 18 0
34 9/8 8 4 7 0
37 6/6 6 1 2 2
38 8/6 6 4 4 5
39 20/15 8 2 4 0
94/78 51 (54%) 21 (22%) 35 (37%) 7 (7%)
both a rapid progression to renal failure and hearing loss reported by two authors [37, 38] have not been observed
by others (Table 2) [24, 34, 39].[6–8]. The anterior lens surface is best examined with a
slit lamp. At fundus examination, lenticonus appears as The ocular abnormalities associated with AS are
readily accounted for by the presence of type-IV collagena central shadow in the red reflex, like an oil droplet on
water. Lenticonus is never present at birth; it develops containing the a3, a4, and a5 chains in the basement
membranes of the lens capsule, retina (Bruch’s mem-slowly during adolescence and can produce axial myopia
and occasionally lens opacities or spontaneous rupture brane and internal limiting membrane), and cornea (epi-
thelial and endothelial) [11, 41–43]. Just as in the GBM,of the anterior capsule [6–8]. The latter complication is
accounted for by the marked thinning of this capsule a structural defect in the a3, a4, or a5 chain might pre-
vent or disturb their incorporation in the ocular base-[35]. Lensectomy and intra-ocular lens replacement are
sometimes required. ment membranes and thus increase their fragility in the
Macular flecks appear as bilateral, faint, whitish or lens, or corneal epithelium, or modify their appearance
yellowish dot-like lesions in the perifoveal area or mid- as retinal flecks or posterior polymorphous dystrophy.
periphery of the retina [36]. They were present in 37% Leiomyomatosis. In 35 patients from 19 families re-
of the young patients reported in five series (Table 2) viewed by Antignac and Heidet, a juvenile-type X-linked
[24, 34, 37–39]. Although often associated with deafness AS was associated with diffuse esophageal leiomyo-
and lenticonus, retinal flecks may be the only extrarenal matosis, mainly manifested by dysphagia or retrosternal
manifestation of AS and thus constitute a valuable ele- pain [13]. Leiomyomatosis also can involve the tracheo-
ment in the diagnostic approach. They should not be bronchial tree and female genitalia and is associated with
confused with albipunctatus retinopathy seen in other congenital bilateral cataracts. Using molecular biologic
disorders, including familial interstitial nephritis [40]. methods, this same group found a deletion involving the
Absent during infancy, retinal flecks develop with time. two first exons of COL4A6 and a variable part of the
They do not impair vision; electrophysiologic and fluoro- contiguous 59 end of COL4A5 [13]. Leiomyomatosis is
angiographic evaluation yield normal results [8]. as severe in females as in males, whereas renal involve-
Recurrent corneal erosion has been observed in 23% ment is milder in females, just as in X-linked forms with-
of 44 patients with severe AS (all were deaf and 38 out leiomyomatosis [44]. The role of the COL4A6 muta-
had reached end-stage renal failure) [33]. We found it tion in the development of this smooth-muscle-cell
interesting that the first episode of corneal erosion pre- tumoral process remains to be elucidated.
ceded the diagnosis of AS in three patients. This compli-
Morphologic featurescation is characterized by attacks of acute ocular pain,
photophobia, and tearing, a triad of symptoms that gen- Study of the kidney by light microscopy and conven-
tional immunofluorescence provides no specific clue toerally first occurs between the ages of 12 and 21 [33].
Episodes are triggered by outdoor activity during windy the diagnosis of AS. These methods do help exclude other
nephropathies. The renal architecture is preserved inconditions, lack of sleep, long periods of ocular concen-
tration, and use of contact lenses. Slit-lamp examination younger patients with AS; a picture of “mixed nephritis”
combining interstitial fibrosis and segmental glomerulo-discloses localized abrasion of the corneal epithelium
and occasionally a detached flap. Outside the erosion, nephritis develops with increasing age [6]. Foam cells,
once considered quite suggestive of AS, are in fact ob-the cornea appears normal or shows occasional intraepi-
thelial microcysts [33]. A history of recurrent corneal served in many other glomerular diseases associated with
heavy proteinuria [8]. Immune deposits usually are absent;erosion does not correlate with the presence of lentico-
nus or retinal flecks [33]. Endothelial vesicles compatible traces of IgM, C3, or both have been observed [8, 24].
By contrast, electron microscopic studies have revealedwith posterior polymorphous dystrophy of the cornea,
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Table 3. Typical distribution of the six a(IV) collagen chains incharacteristic alterations of the GBM [45]. Over the past
selected renal and skin basement membranes from normal
10 years, the development of specific antibodies has per- individuals and AS patients (hemizygotes and AR homozygotes)a
mitted the detection of each a(IV) chain in the basement
a1 a2 a3 a4 a5 a6membranes of kidney and skin. At present, immunohis-
Normaltochemistry is a new, useful tool for the diagnosis of AS.
GBMb 1 1 1 1 1 2
Ultrastructure of the GBM. The most characteristic Bowman’s capsule 1 1 1/2 1/2 1 1
Distal tubule 1 1 1/2 1/2 1 1histologic feature of AS is variable thickness of the GBM
Collecting duct 1 1 2 2 1 1with lamellation of the lamina densa often circumscribing
EBM 1 1 2 2 1 1
clear areas containing electron-dense granules (Fig. 2). Hemizygote
GBM 1 1 2 2 2 2The GBM width, which normally is 350 nm, can be as
Bowman’s capsule 1 1 2 2 2 2thick as 1200 nm or as thin as 100 nm. Its inner and
Distal tubule 1 1 2 2 2 2
outer contours are irregular; thick and thin segments Collecting duct 1 1 2 2 2 2
EBM 1 1 2 2 2 2can alternate. The specificity of these changes has been
AR homozygotequestioned since segmental areas of GBM splitting have
GBM 1 1 2 2 2 2
been observed in various immune-complex glomerulo- Bowman’s capsule 1 1 2 2 1 1
Distal tubule 1 1 2 2 2 2nephritides [7]. Furthermore, diffuse thickening of the
Collecting duct 1 1 2 2 1 1GBM occurs in diabetic nephropathy [46] and in the
EBM 1 1 2 2 1 NDc
nail-patella [30] and Cockayne syndromes [47]. Still, in
a From Refs. 2, 10, 11, 43, 52–56the absence of the latter disorders, extensive thickening b GBM: glomerular basement membrane; EBM: epidermal basement mem-
braneand splitting of the GBM, together with the absence of
c ND: not determinedimmune deposits, strongly suggest the diagnosis of AS.
This ultrastructural appearance can precede the abnor-
malities detected by light microscopy, but it is found in
only 60% to 90% of patients with AS [48, 49]. In the presence in the collecting duct; the a6(IV) chain co-
localizes with the a5(IV) chain except for its notablemajority of the remaining patients, the GBM appears
uniformly thin; in some others, unspecific lesions or no absence in the GBM (Table 3) [2, 10, 11, 43, 52–56].
The absence of a5(IV) in the GBM was expected inlesion at all is detected [49]. Thinning can be the first
stage of GBM alteration; thus, sequential biopsies in a the X-linked AS, whereas that of a3(IV) or a4(IV) was
anticipated in the autosomal-recessive form. In fact,male patient at ages 9 and 18 years revealed a progression
from diffuse attenuation in the first sample to character- GBMs lacking a5(IV) also failed to express the a3(IV)
and a4(IV) chains with a few exceptions (Table 3) [2, 7,istic thickening and lamellation in the second [50]. In
some families, X-linked as well as autosomal-recessive, 11, 52]. In other words, a mutation affecting one of the
three chains prevents the expression not only of thatdiffuse thinning is the only GBM abnormality, even until
adulthood [2, 48]. Diffuse GBM thinning is the hallmark chain but also of the other two. Possible explanations
for this phenomenon have been discussed elsewhere [7, 9].of another clinical entity known as benign familial hema-
turia. In AS, diffusely thin GBM is often associated with It is generally assumed that a specific a3-a4-a5 network
exists in the GBM, and that a mutation in one of thea milder phenotype and less severe mutations: 36% of
25 patients with thin GBM studied by Gubler et al were three chains prevents the incorporation of the two others
into a stable heterotrimer, resulting in their degradationnot deaf versus only 5% of 57 with thick GBM [48]; all
seven patients with thin GBM reported by Nakanishi [7, 9]. Whatever the explanation, the co-absence of a3
(always concordant with a4) and a5 in the GBM is aand colleagues had adult-type AS versus only one of 16
with thick GBM [51]. This pattern is not a rule, however; major diagnostic clue to AS, because it has not been
described so far in other nephropathies, including mini-a major rearrangement was recently reported in a patient
with no significant lesion in the GBM [49], and discordant mal-change disease, immune-complex glomerulopathies,
diabetic nephropathy, and thin-basement-membrane ne-ultrastructural findings have been observed among af-
fected relatives in several families [48, 49]. In sum, the phropathy [7, 43, 54, 55]. This finding is especially helpful
when the GBM ultrastructural appearance is equivocal.ultrastructural pattern correlates, but not strictly, with
clinical severity and magnitude of mutation. As a result of random X-chromosome inactivation, XL
heterozygotes most often express a3 and a5 mosaicallya(IV) chains in the kidney. Expression in the normal
kidney of the four a(3-4-5-6) chains of type-IV collagen [7, 43, 48, 51]; the degree of a5 expression seems to
correlate negatively with the severity of renal disease [57].encoded by the genes defective in AS varies among neph-
ron segments. The a3 and a4 chains are expressed in Although specific, the absence of both a3 and a5 in
the GBM is not a sensitive clue for AS. A faint or eventhe GBM, Bowman’s capsule, and distal tubule, but not
in the proximal tubule, Henle’s loop, and collecting duct; normal staining for both a3 and a5 is indeed observed
in about 20% of hemizygotes and AR homozygotesthe a5(IV) chain has the same distribution except for its
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[2, 40, 49]. These patients usually have a milder pheno- paraffin-embedded sections using the immunoperoxi-
type [48, 51], diffuse GBM thinning [48, 51], and less dase method also has been performed successfully, pro-
severe mutations in the COL4A5 gene (mis-sense and vided the reactive epitopes are previously restored by an
small in-frame deletion/insertion) [49, 58]. In addition, antigen retrieval procedure [58]. A recently established
although the expression of a3 and a5 in the GBM is fluorochrome-conjugated monoclonal antibody against
usually concordant, the presence of a3 in the absence the triple-helical domain of a5(IV) reportedly is usable
of a5 has been reported in seven families [49, 51], two in direct staining without urea pre-treatment [60].
of whom had a COL4A5 mutation, a glycine substitution
Genetic diagnosisin the triple helix in both cases [49].
Clearly, the pattern of a3-a5 chains in the GBM does Genetic analysis provides the only conclusive diagno-
not differ between the X-linked and the autosomal-reces- sis of AS. As I already mentioned, direct mutation detec-
sive form. By contrast, the study of a(IV) chains in the tion in AS remains a challenge for the molecular biologist
extraglomerular basement membranes might help differ- because of heterogeneity of the locus (several genes)
entiate both forms of AS. In Bowman’s capsule and and allele (many different types of mutation in the same
the collecting duct, both a5 and a6 are expressed in gene) in addition to the huge size of the genes (51 exons
autosomal-recessive AS but are absent in the X-linked to be screened). Until recently, about 50% of mutations
form (Table 3) [2, 56]. This pattern might be explained affecting the most frequently involved gene, COL4A5,
by the normal scarcity (in Bowman’s capsule) or the remained undetected [61–63]. Using PCR and direct
absence (in the collecting duct) of a3 and a4 chains at DNA sequencing of all exons, including extended intron
these sites. A mutation in the COL4A3/A4 genes is thus sequences, Martin et al have just recently reported a
expected to interfere less severely or not at all with mutation detection rate of 82% [64]. Nevertheless, until
a5(IV) expression, as compared with GBM in which a3 advances are made in speed and yield of the techniques
and a4 form heterotrimers with a5. This distinction is used for genetic mutation screening, we will have to rely
not absolute, however; a pattern characteristic of the on the indirect approach, genetic linkage analysis [65].
autosomal-recessive form has been reported in a few Linkage analysis. Linkage of a disease to a genetic
patients with a splice site of a mis-sense mutation of locus relies on the demonstration of the co-segregation,
COL4A5 (Gubler MC, personal communication) [58]. in a given family, of the disease with a genetic marker
a(IV) chains in the skin. The a5 and a6(IV), but not or set of markers (DNA sequences known for their poly-
the a3 and a4(IV), chains are expressed in the epidermal morphism) flanking or within the gene. DNA markers
basement membrane (EBM) [4, 51, 53, 55], so biopsy
mainly include restriction fragment length polymorphisms
examination of the skin can be valuable in the diagnosis
(RFLP) and sequences containing a variable number ofof AS [7].
simple repeat elements, such as a dinucleotide tandemThe expression pattern of a5(IV) is the same in the
repeat (DNTR), for example, the repeating unit CA.GBM and EBM from patients with X-linked AS, whether
For COL4A5, many markers near or within the genehemizygotes [43, 51] or heterozygotes [57]. A case of
have been identified [65]. We routinely use 4 DNTR:2B6,discordant pattern (the presence of a5 in the EBM despite
which is intragenic; DXS456, which is proximal; andits absence in the GBM) nevertheless was reported in two
DXS1191 and DXS1106, which are distal to COL4A5,related hemizygotes [59]. Still, the absence of a5(IV) from
as primary markers. Additional markers are used whenthe EBM appears highly specific for X-linked AS; this
primary markers are not sufficiently informative. A smallerfinding has not been reported so far in other conditions.
number of intragenic and flanking markers for theAmong XL heterozygotes expressing a5 mosaically, the
COL4A3/A4 genes are available [14, 15]. We currentlydegree of expression—quantified as the percentage of
use a CA repeat and a COL4A4 intragenic RFLP [14].EBM length stained by anti-a5(IV) antibodies—inversely
In genetic linkage analysis, the accuracy of the result—correlates with the severity of renal involvement, as as-
expressed as a likelihood of linkage versus non-linkage—sessed by proteinuria [57]. In AR homozygotes, a5(IV) is
depends on several factors: the a priori probability foralways expressed in the EBM, just as in extraglomerular
linkage (based both on the frequency of the tested ge-basement membranes within the kidney [2].
netic form in the relevant population and on the individ-Valid immunohistochemical examination of kidney
ual pedigree), the correct identification of affected orand skin with antibodies against a(IV) chains requires
non-affected family members, the number of tested indi-experience with this technique [7]. Staining is generally
viduals, and the informativeness of the markers. Forstudied in fresh-frozen sections using the indirect immuno-
example, in a small family, linkage to COL4A5 mightfluorescence method. To reveal epitopes, sections have to
only be likely or very likely. In that case, the exclusionbe treated with 6 M urea prior to exposure to primary
of linkage to COL4A3/A4 would reinforce the probabil-antibodies. Parallel staining of control tissues side by
side with patient tissues is recommended [7]. Staining of ity of linkage to COL4A5. Potential pitfalls in linkage
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data are non-paternity and the occurrence of new muta- A regular and diffuse thinning of the GBM, with a
mean GBM thickness of less than 260 nm, occurs intions, including germ-line mosaı¨cism [65].
Mutation screening. Only a handful of mutations have patients with benign familial hematuria in the absence
of other specific lesions on light and immunofluorescencebeen identified in the COL4A3/A4 gene. Therefore, I
will only mention the current strategy used to detect microscopy [70, 71]. Staining of the GBM for both
a3(IV) and a5(IV) is normal or only slightly reducedmutations in the COL4A5 gene. Only large and medium-
sized deletions are easily detected by a simple technique, [60, 70, 72]. An increased percentage of sclerotic glomer-
uli has been reported in some patients [73]. The preva-that is, Southern blotting analysis using overlapping
cDNA probes spanning the entire gene. This first step lence of thin GBM was found to be similar to that of
IgA nephropathy among Dutch patients biopsied forin mutation screening can identify only 2% to 15% of
COL4A5 mutations [12, 62, 66]. More sophisticated chronic hematuria [71]. Recent information suggests
first, that benign familial hematuria might not be so “be-methods are used subsequently for the diagnosis of other,
small mutations. Since there is no “hot spot,” the whole nign” in the long-term, and second, that it could belong,
at least for a subset a patients, to the spectrum of AS.gene has to be examined exon by exon. The screening
methods have been reviewed by Lemmink et al [12] Most patients with a thin GBM only have lifelong
microscopic hematuria, but gross hematuria, proteinuria,and Renieri and De Marchi [67]. The most widely used
method is the single-strand conformation polymorphism and renal failure have been occasionally reported [74, 75].
Among 17 normotensive patients with thin GBMs fol-analysis (SSCP) after PCR amplification of each exon;
this technique relies on the observation that a denatured lowed for 12 years, seven became hypertensive and one
of these developed mild renal failure; second biopsiesDNA sample subjected to migration through a gel matrix
has a different conformation, and therefore a different in three patients revealed unchanged thin GBMs but
increased focal glomerulosclerosis [73].mobility, if its nucleotide sequence is modified. This step
is followed by sequencing the abnormal exon [61–63, The similarity of GBM abnormality in benign familial
hematuria and in early AS together with the frequent67]. Direct DNA sequencing after PCR amplification of
all exons is now recommended as the most effective presence of microscopic hematuria in AS heterozygotes
led to the hypothesis that patients with thin GBM ne-approach [64]. As I already mentioned, many mutations
have been recognized; only a few have been recorded phropathy were in fact AR heterozygotes; this hypothe-
sis also would account for the dominant transmission ofmore than once in different families.
this abnormality [14]. This route of transmission was
Use of the genetic diagnosis demonstrated in a Dutch family in which a mis-sense
mutation in the collagenous domain of COL4A4 co-Given their complexity and cost, the use of methods
currently available for genetic diagnosis is restricted to segregated with microscopic hematuria [14]. Unfortu-
nately, only the patient suspected of being a compoundselected cases. In families with an established diagnosis
of AS, genetic diagnosis can clarify the mode of transmis- heterozygote had a renal biopsy, which showed GBM
abnormalities typical of AS. By contrast, investigationsion, which is of crucial importance for genetic counsel-
ing. Genetic diagnosis also can ascertain the status of an of four Japanese families with biopsy-proven thin GBM
nephropathy failed to show linkage to COL4A3 markersXL heterozygote for the purposes of family planning or
kidney donation and provide prenatal diagnosis. Both [76] and suggested the implication of other genes. Ongo-
ing studies of similar families in Europe should clarifydirect identification of the mutation [68] and gene link-
age [69] have been used for prenatal diagnosis of juvenile the intriguing relationship between AS and thin GBM
nephropathy.AS. Detection of mutation also might be the only way
to establish the diagnosis of AS in the occasional patient
Autosomal-dominant ASin whom uncertainty remains after extensive clinical
evaluation. A rare form of autosomal-dominant, progressive hema-
turic nephritis associated with deafness, macrothrombo-
Thin GBM nephropathy cytopenia (Epstein’s syndrome), and sometimes granulo-
cyte inclusions (May-Hegglin anomaly or Fechtner’sAs I said earlier, the GBM can be diffusely thin in
AS, either as an early change preceding thickening [50] syndrome) has been reported. Gregory et al reviewed
data from 13 families [18]. Ultrastructural appearance ofor as the only persistent lesion in some X-linked as well
as in some autosomal-recessive [2, 48] kindreds. Thin the GBM, reported in five cases, is suggestive of AS [18];
the distribution of a(IV) chains, reported in three cases,GBM is also observed in a reportedly different condition
called “benign familial hematuria,” characterized by iso- is normal [77]. In the absence of molecular biologic data,
the relationship of this entity to AS remains uncertain.lated, persistent microscopic hematuria without extrare-
nal abnormalities, transmitted as an autosomal-domi- In a few AS kindreds without hematologic abnormali-
ties, the occurrence of male-to-male transmission hasnant trait [70].
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Table 4. Diagnostic value of clinical and pathologic features in AS ble, the screening of first-degree relatives (at least for
microscopic hematuria) and, in the proband, a carefulPathognomonic
Anterior lenticonus eye examination and an audiogram. Isolated microscopic
Absent (hemizygotes) or discontinuing staining (XL heterozygotes) for hematuria in the proband’s mother is consistent with
a5(IV) in the EBMa
both forms of AS; its presence in the proband’s fathera3 2 a4 2 a5(IV) in the GBM
Highly suggestive suggests an autosomal-recessive form; found in two gen-
Retinal flecks erations with male-to-male transmission, isolated micro-History of recurrent corneal erosion
scopic hematuria points to a diagnosis of benign familialGBM thickening and splitting
Suggestive hematuria.
Sensorineural deafness The diagnostic value of each extrarenal abnormalityGBM diffuse thinning
is summarized in Table 4. Anterior lenticonus (virtually
a EBM: epidermal basement membrane; GBM: glomerular basement mem-
always associated with deafness), the only pathogno-brane
monic extrarenal feature, is found in only 10% to 30%
of affected patients. In its absence, the likelihood of the
diagnosis is very high in the presence of three or even
suggested the existence of an autosomal-dominant form two other characteristic clinical features (Table 4). For
[15, 49, 65]. The likely candidate genes are, of course, example, the combination of retinal flecks and sensori-
the COL4A3/A4 genes, responsible for the autosomal- neural deafness strongly predicts AS.
recessive form of AS. Mutation in another collagen gene, The next step in diagnosing AS relies on pathologic
COL11A2, was shown to lead either to recessive or domi- evidence. Skin biopsy is less invasive than renal biopsy
nant disease, according to the type of mutation [78]. To and should be performed first. The absence of a5 in the
the best of my knowledge, linkage to the COL4A3/A4 EBM, observed in about 80% of hemizygotes, or the
genes has been reported in only one family with autoso- discontinuous pattern characteristic of the corresponding
mal-dominant AS; in this family, AS was of the adult XL heterozygotes (although less easily recognized) is
type, and extrarenal involvement was restricted to mild pathognomonic of X-linked AS. Normal staining (either
deafness in a single affected individual [15]. in hemizygotes or XL heterozygotes) does not exclude
Before establishing a diagnosis of autosomal-dominant a diagnosis of X-linked AS.
AS, one should consider the possibility of other autoso- If the diagnosis is not yet established, renal biopsy
mal-dominant progressive glomerulonephritides unre- most often provides it. Diffuse thickening and splitting
lated to AS. One of them, recently recognized, is focal of the GBM, observed in 60% to 90% of AS patients,
segmental glomerulosclerosis, clinically characterized by strongly suggests AS. Diffuse thinning, observed in the
long-standing proteinuria before ESRF and the absence majority of remaining affected individuals, is compatible
of extrarenal abnormalities [79]; this entity is genetically with either AS (early stage or not) or thin GBM disease.
distinct from AS (abstract, Pirson et al, Nephrol Dial Normal ultrastructure of the GBM makes the diagnosis
Transplant 13:A103, 1998). of AS very unlikely. The interpretation of staining for
a3-a5(IV) in the kidney is summarized in Table 3. Again,
Diagnostic approach normal staining, found in 15% to 20% of AS patients,
How should we approach the diagnosis of AS? I will does not exclude the diagnosis of AS. If the diagnosis
consider first the apparently sporadic patient suspected remains doubtful (and sophisticated genetic laboratory
of having AS in whom the diagnosis and the mode of testing is available), one could consider screening for a
transmission have yet to be established. Second, I will genetic mutation. Screening should be started with the
consider the at-risk individual from a known AS family. COL4A5 gene, unless a recessive form is suspected.
I will talk about only the two main forms of AS, namely, Screening of first-degree relatives is critical. The fol-
X-linked and autosomal-recessive AS. lowing findings suggest an autosomal-recessive form:
When should we suspect an apparently sporadic case consanguinity of the parents, no abnormality or only mild
of AS? Alport’s syndrome should be considered in any abnormalities in the parents (most often microscopic
child with unexplained, persistent microscopic hematuria hematuria, sometimes mild hearing loss), or severe dis-
of glomerular origin, with or without a history of gross ease of a female proband with ESRD before the age of
hematuria. Alport’s syndrome also should be kept in 20. The autosomal recessive form differs from the typical
mind in an adult with a clinical or pathologic picture of X-linked form by the presence of a5(IV) chain, both in
unspecified chronic glomerulonephritis. The presence of some extraglomerular basement membranes and in the
an extrarenal abnormality associated with AS (Table 4) EBM (Table 3). The existence of a few exceptions should
obviously raises the index of suspicion, although its ab- be kept in mind.
sence does not rule it out. How should we confirm the diagnosis of AS in an at-
risk member of a family with AS? In a family with X-The clinical workup should include, whenever possi-
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linked AS, early diagnosis among at-risk males (that QUESTIONS AND ANSWERS
is, 50% of the children from a heterozygote mother) Dr. John T. Harrington (Dean, Tufts University
generally is easy; persistent microscopic hematuria ren- School of Medicine, Boston, Massachusetts, USA): Thank
ders the diagnosis of AS very likely (provided that uro- you, Yves, for a superb review of the genetic profile of
logic causes have been ruled out), whereas its absence Alport’s syndrome. Is there any information regarding
virtually excludes it. The presence of one extrarenal sign genetic alterations in type-IV collagen in patients with
GBM thickening due to a systemic disease such as diabe-of the disease, including EBM immunostaining for
tes? Might such alterations play a contributory role ina5(IV), is confirmatory (Table 4). In at-risk females with-
that disorder?out renal or extrarenal signs of AS, linkage analysis is the
Dr. Pirson: I am not aware of the existence of specificmost reliable method of formally excluding the genetic
genetic alterations in type-IV collagen in diabetics devel-diagnosis of asymptomatic carrier.
oping GBM thickening. But it is noteworthy that theIn a family with autosomal-recessive AS, normal uri-
composition of the thickened GBM differs between thenalysis excludes homozygosity; microscopic hematuria is
two conditions. In AS, a1(IV) and a2(IV) chains, nor-found in all homozygotes and in about one-half of the
mally confined to the subendothelial region of GBM,heterozygotes. Severe renal and extrarenal involvement
extend throughout the full width of GBM, along withis only found in homozygotes. If the diagnosis remains
type-V and type-VI collagens [7]. Such changes are notdoubtful, linkage analysis should be performed.
present in diabetic nephropathy [81].
Dr. Harrington: Has gene replacement therapy beenConclusion
explored in animal models? Do you foresee any role for
The history of Alport’s syndrome illustrates the impact gene therapy in humans, and what are the obstacles?
of molecular biology on our comprehension and classifi- Dr. Pirson: Four different animal models of AS are
cation of renal disorders. Described more than 60 years available, three in dogs and one generated in mutant
ago as a syndrome associating hereditary renal disease mice. In the Samoyed dog model, which has been thor-
and deafness [80], AS became a family of diseases with oughly characterized, AS is X-linked and due to a single
blurred outlines. The discovery of its molecular determi- base mutation in the COL4A5 gene producing a prema-
nants has provided a diagnostic gold standard and given ture stop codon [82]. Two models exist for the autosomal
us an understanding of the various components of the recessive form: a COL4A3 knockout mouse [83] and a
naturally occurring disease in the English cocker spanielclinical syndrome. A disease of type-IV collagen, AS en-
dog [84]. Last, an autosomal-dominant form has beencompasses several varieties defined by the corresponding
reported in the bull terrier dog [85].defective gene: X-linked disease due to mutation in the
Alport’s syndrome is a conceptually attractive diseaseCOL4A5 gene, X-linked disease with diffuse leiomyo-
for testing the potential of gene therapy. The fact thatmatosis due to contiguous mutation in the COL4A5 and
XL as well as AR heterozygotes usually do not developCOL4A6 genes, and autosomal-recessive disease due to
renal failure indeed suggests that provision of a normalmutation either in the COL4A3 or the COL4A4 gene.
copy of the gene could prevent progressive renal disease.For each of these varieties, the discriminant value of asso-
This has yet to be demonstrated in animal models. Theciated clinical findings, family history, ultrastructural as-
obstacles to successful gene therapy are numerous, rang-pect of the GBM and, more recently, the staining pattern
ing from the difficulty of effectively targeting the appro-for a(IV) chains in kidney and skin basement membranes
priate kidney cells, to the problems related to the controlhas been evaluated, so that the clinician is now able to
of the expression of the transferred gene so as to obtain
confidently establish the diagnosis of AS in a majority
a correct incorporation of the collagen chain into GBM
of patients on clinical and pathologic grounds. In the [86]. As an encouraging first step forward, Tryggvason
remaining cases, in which the diagnosis remains uncer- and colleagues recently reported 85% transfer efficiency
tain, genetic techniques may provide the ultimate answer. of a reporter gene carried by an adenovirus vector into
Despite this impressive progress, the diagnosis re- in vivo perfused pig glomeruli [86]. Prior to the advent
mains elusive in a few cases, and the borders between of gene therapy, animal models will help us to test the
autosomal-recessive AS, benign familial hematuria, and effect of pharmacologic interventions such as ACE in-
autosomal-dominant AS are yet to be delineated. Other hibitors.
components of the GBM, such as laminin, nidogen, and Dr. Jerome P. Kassirer (Editor-in-Chief, New Eng-
proteoglycans might be involved. Further elucidation of land Journal of Medicine, Boston, Massachusetts, USA):
the molecular basis of the various autosomal varieties Aside from the intellectual satisfaction, are there any
of AS will undoubtedly widen our understanding of he- therapeutic implications of a specific histologic and ge-
netic diagnosis of the type of Alport syndrome?reditary nephropathies.
Nephrology Forum: Alport’s syndrome 771
Dr. Pirson: So far the diagnosis of AS has no direct Dr. Pirson: This syndrome differs from classic AS
by its autosomal-dominant inheritance and the normaltherapeutic impact, narrowly defined. Nevertheless, rec-
ognition of the disease and identification of its mode of expression of a(IV) chains in the GBM [18, 77]. Only
the identification of the molecular basis of this disordertransmission have significant implications in terms of
prognosis and genetic counseling of the patient and the will reveal whether it is simply a variant of AS or a
separate entity.extended family.
Sir Keith Peters (Regius Professor of Physics, Univer- Dr. Toshio Miyata (Associate Professor of Medicine,
Tokai University School of Medicine, Kanagawa, Japan):sity of Cambridge, Cambridge, UK): As your presenta-
tion indicated, precise clinical and genetic characteriza- You ascribed the wide range of severity of AS observed
in XL heterozygotes to the random inactivation of thetion also has important implications for living-related
organ donation, as well as for the risk of subsequent X chromosome. We also found the effect of random
inactivation of the X chromosome in paroxysmal noctur-anti-GBM disease in the graft.
Dr. Pirson: You rightly emphasize that ascertaining nal hemoglobulin (PNH), which is an acquired hemato-
logic disorder. Paroxysmal nocturnal hemoglobulinuriathe status of XL or AR heterozygotes by linkage analysis
or identification of the mutation has important implica- is caused by the somatic mutation of PIG-A gene on X
chromosome [90]. However, the incidence of PNH istions for kidney donation. The type of mutation also has
an impact, although modest, on the risk of developing equal between males and females because of random
inactivation of the X chromosome. Therefore, I agreeanti-GBM disease after renal transplantation. Let me
first stress that the risk of graft loss from anti-GBM that the random inactivation mechanism of the X chro-
mosome functions in the pathology. Could you commentdisease often has been exaggerated. In our experience
with more than 50 patients who received renal trans- on the random inactivation of the X chromosome in XL
heterozygotes with AS? Do one or more nongeneticplants for AS, no graft has been lost so far from anti-
GBM disease [87], despite the fact that in about 15% of mechanisms account for the wide range of severity of
AS in XL heterozygotes?the grafts the presence of a linear glomerular deposit of
IgG reflects a mild immunization against GBM [87, 88]. Dr. Pirson: Let me first remind us that the variable
severity of the expression of an X-linked disorder inThe clinical and genetic profile of the 3% of AS patients
who develop crescentic anti-GBM nephritis with even- heterozygotes can depend both on genetic factors, that
is, the type of mutation and the modifying genes, andtual graft loss has been recently reviewed by Kashtan and
Michael [7] and Lemmink and colleagues [12]. Roughly, non-genetic factors. However, a major determinant of
this variability seems to be the individual pattern of X90% are males with a juvenile-type XL disease and 10%
are AR homozygotes. Nearly all patients have a mutation inactivation. As you know, the inactivation of one of
the two X chromosomes takes place very early duringresulting in a truncated a(IV) chain lacking the NC1
domain. Still, the majority of patients with a mutation embryogenesis and is random between the maternal and
paternal X chromosomes. As a result, most females havedeleting a large part of COL4A5, COL4A3, or COL4A4
(including the NC1 domain) do not develop anti-GBM a mosaic expression of maternal and paternal alleles of
X loci, with a mean contribution, at a population level,nephritis. Thus, factors other than the type of mutation
must influence the immune response to the graft. In of 50% from each chromosome. However, a substantial
deviation from this 50:50 population distribution, orpractice, the discovery of such a mutation should not
contraindicate renal transplantation [7, 12, 66]. Of note, “skewing,” is observed in 5% to 20% of individual
women [91]. Preponderant inactivation of the normal Xthe target of antibodies developed in hemizygotes
against graft GBM is generally, as expected, the NC1 chromosome therefore could account for a severe pheno-
type in XL heterozygotes, such as in the patient reporteddomain of a5(IV) [89]; such antibodies are therefore
not recognized by commercial ELISAs for anti-GBM by Guo et al, in whom 90% of the X chromosomes
carrying the normal COL4A5 allele were inactivated,antibodies in which the ligand is a purified preparation
of a3(IV) NC1 domains (the Goodpasture antigen). both in kidney and white blood cells [92]. The elucidation
of the processes leading to X inactivation skewing shouldDr. Christopher Winearls (Chief, Renal Unit, Ox-
ford Radcliffe Hospital, Oxford, UK): Do pregnancies enlighten our understanding of the phenotypic heteroge-
neity among XL heterozygotes.affect the renal prognosis of X-linked Alport syndrome
patients? Dr. Jean-Pierre Gru¨nfeld (Chief, Renal Unit, Hoˆpi-
tal Necker, Paris, France): We know that approximatelyDr. Pirson: I am not aware of any study on the effect
of pregnancy on the renal outcome of XL heterozygotes. 12% of the heterozygote women with X-linked AS pro-
gress to renal failure. In your opinion, what are the bestDr. Jacques Bernheim (Chief, Renal Unit, Meir Hos-
pital, Kfar Saba, Israel): You mentioned the Epstein predictors of progression in a 20-year-old affected
woman?syndrome briefly. Do you think that this disease really
is a separate entity? Dr. Pirson: The strongest predictors remain those that
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you identified more than 10 years ago: a history of gross sion, or sensorineural deafness. They should not be ac-
cepted as kidney donors.hematuria, the nephrotic syndrome, and a diffuse thick-
Dr. Joseph Rosenfeld (Chief, Institute for Preventiveening of the GBM [19]. An additional parameter could
Cardiology, Tel Aviv University Medical School, Telbe the degree of (a5)IV expression, measured either in
Aviv, Israel): Following Charles van Ypersele’s question,the GBM or the EBM. Nakanishi has indeed reported
I would like to add that living-related donor transplanta-that this expression is inversely correlated with the sever-
tion in an AS patient has an excellent prognosis. Ourity of renal involvement [57]. If this observation is con-
first such patient received a kidney from his mother.firmed, quantification of (a5)IV expression in the EBM
He survived for 33 years with an excellent creatininecould become a useful predictor of renal outcome in XL
clearance and eventually died from chronic hepatitis.heterozygotes.
Dr. Harrington: Could you speculate further on theDr. Tilman Dru¨eke (Director of Research, INSERM
relationship between thin-basement-membrane (TBM)U90, Hoˆpital Necker): In the mouse knockout model
disease and AS? Will nearly all TBM disease patientsof autosomal-recessive AS, is the glomerular basement
turn out to have AS?membrane either thin or thick or both? Is there a pro-
Dr. Pirson: We should first be aware that in the litera-gression from thin to thickened membrane with time?
ture there is a problem of definition of thin GBM, be-Dr. Pirson: The COL4A3 knockout mouse is an excel-
cause pathologists rely on different cut-off points andlent model for following the course of GBM alterations.
different examination methods. As we have just dis-As in human disease, there is clearly a progression from
cussed, thin GBM can be the temporary or, more rarely,GBM thinning, beginning in the external capillary loops,
the persistent expression of a true AS, that is, a diseaseto extensive thickening and lamellation. As in human
that will progress to glomerulosclerosis and renal failure.disease also, GBM lacks a4(IV) and a5(IV) chains, al-
Thin GBM also can be the sole pathologic counterpartthough mRNAs encoding these chains normally are pres-
of so-called benign familial hematuria, a subset of whichent [83]. Similar observations have been made in the dog
might be—at least in Japan—unrelated to type-IV colla-model of autosomal-recessive AS [84]. Both in the mouse
gen genes [76]. This latter finding is consistent with theand dog models, heterozygotes exhibit a normal GBM
loss of anionic charge in the GBM documented by Goelappearance [83, 84].
et al in patients with ultrathin GBM and attributed toDr. Marie-Claire Gubler (Director of Research,
an alteration of proteoglycans [93]. My guess is that TBMINSERM Unit 423, Hoˆpital Necker): In your diagnostic
will be divided into subentities according to the involvedstrategy, you consider immunohistochemical changes of
GBM component. Marie-Claire, you are the best expertthe GBM or EBM as pathognomonic of AS. I agree
in the field. What do you think?
with you. I feel that this feature has become a definitive
Dr. Gubler: Indeed I do believe that thin GBM is
criterion for AS. I also want to emphasize that ultrastruc- not a disease but only an ultrastructural finding that
tural findings also have a high diagnostic value when may correspond to various types of nephropathy. As a
they are observed in the absence of other pathologic pathologist, I can identify the lesion, but not necessarily
changes and when they are widespread, for example, in the disease.
a child with isolated hematuria. Dr. Ju¨rg Schifferli (Professor of Medicine, University
Dr. Pirson: I agree. Thank you for your comment. Hospital Basel, Basel, Switzerland): What is so special
Dr. Charles van Ypersele (Professor Emeritus, Re- about type-IV collagen that it is included in the basement
nal Unit, Cliniques Universitaires St-Luc, Brussels, Bel- membranes of kidney, eye, and ear? Has it a specific
gium): This patient was transplanted with her mother’s property or function?
kidney. This is easy to understand because the diagnosis Dr. Pirson: Type-IV collagen is the major component
of AS was not known at that time. What would be your of basement membranes and is almost exclusively found
attitude today if you knew the diagnosis? in these structures. While a1(IV) and a2(IV) are present
Dr. Pirson: The vast majority of AR heterozygotes in all basement membranes, a3–a6(IV) have a restricted
will remain asymptomatic carriers. In those without mi- tissue distribution [10]. The latter, however, are not con-
croscopic hematuria, there is no reported case of progres- fined to basement membranes of kidney, eye, and ear;
sion to renal failure; kidney donation thus should be they also are expressed, for example, in brain, lung, and
accepted without hesitation. Those AR heterozygotes synaptic muscle fibers [10]. The specific biologic role of
who have isolated microscopic hematuria have a very type-IV collagen has yet to be elucidated. In vitro studies
small risk of developing late renal failure. In that case, have shown that type-IV collagen has the ability to bind
I would express some reservation about kidney donation integrins and to adhere to a variety of cells [10].
but would be ready to accept it from a strongly moti- Dr. Mohamed Ben Hmida (Assistant Professor, De-
vated, well-informed donor. Rare heterozygotes have partment of Nephrology, Sfax Hospital, Sfax, Tunisia):
What is the mechanism of chronic renal failure in AS?additional manifestations such as proteinuria, hyperten-
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(IV) and a4 (IV) collagen genes in autosomal recessive AlportDr. Pirson: The mechanism of progressive renal scle-
syndrome. Nat Genet 8:77–82, 1994
rosis in AS has yet to be elucidated. As proposed by 2. Gubler MC, Knebelmann B, Beziau A, Broyer M, Pirson Y,
Haddoum F, Kleppel MM, Antignac C: Autosomal recessiveKashtan and Michael [7], accumulation of a1(IV) and
Alport syndrome: Immunohistochemical study of type IV collagena2(IV) chains and subsequently of type-V and -VI colla-
chain distribution. Kidney Int 47:1142–1147, 1995
gens in the GBM could disrupt its filtration properties 3. Flinter FA, Cameron JS, Chantler C, Houston I, Bobrow M:
Genetics of classic Alport’s syndrome. Lancet 2:1005–1007, 1988and explain proteinuria. Kalluri et al recently demon-
4. Hostikka SL, Eddy RL, Byers MC, Ho¨yhtya¨ M, Shows TB,strated that GBMs lacking a3(IV) and a4(IV) chains are
Tryggvason K: Identification of a distinct type IV collagen a chain
less resistant to endopeptidase digestion [94]. Here, too, with restricted kidney distribution and assignment of its gene to
the locus of X chromosome-linked Alport syndrome. Proc Natlobservation of animal models of AS could provide some
Acad Sci USA 87:1606–1610, 1990clues to the understanding of the mechanisms of chronic
5. Ramsay G: DNA chips: State-of-the-art. Nat Biotechnol 16:40–44,
renal failure. 1998
6. Gru¨nfeld JP: Nephrology Forum: The clinical spectrum of heredi-
tary nephritis. Kidney Int 27:83–92, 1985NOTE ADDED IN PROOF 7. Kashtan CE, Michael AF: Alport syndrome. Kidney Int 50:1445–
1463, 1996Boye et al recently reported the complete character-
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